Prescribing Information for Aciphex. Prescribing Information for Protonix. Prescribing Information for Prilosec. Prescribing Information for Prevacid, purple power and nexium. Takeda Pharmaceuticals America Inc. A new esomeprazole packet sachet formulation for suspension: Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations.
Accessed April 18, NEXIUM 40 mg and 20 mg are indicated for short-term treatment 4 to 8 weeks in healing and symptomatic resolution of diagnostically confirmed erosive esophagitis EE.
NEXIUM 20 mg wellbutrin xl and paxil combination therapy indicated to maintain symptom resolution and healing of EE controlled studies did not extend beyond 6 monthsand for short-term treatment 4 to 8 weeks of heartburn and other symptoms associated with GERD.
You may report side effects related to AstraZeneca products by clicking here. Watch Mixing Instructions Watch now. Best Savings Ever Learn more. Important Safety Information NEXIUM is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles Symptomatic response to therapy does not rule out the presence of gastric malignancy, purple power and nexium. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a proton pump inhibitor PPI, purple power and nexium.
This diagnosis should be considered for diarrhea that does not improve PPI therapy may be associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine.
The risk of fracture was increased in patients who received high-dose multiple daily doses and long-term a year or longer therapy Cutaneous lupus erythematosus CLE and systemic lupus erythematosus SLE have been reported in patients taking PPIs, including esomeprazole.
These events included both new onset and exacerbations. Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks Avoid concomitant use of NEXIUM with clopidogrel, due to a reduction in plasma concentrations of the active metabolite of clopidogrel.
When using NEXIUM consider alternative anti-platelet therapy Daily treatment with any acid-suppressing medications over a long purple power and nexium of time eg, purple power and nexium, longer than 3 years may lead to malabsorption of cyanocobalamin vitamin B Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature Hypomagnesemia has been reported rarely with prolonged treatment with PPI therapy and may require discontinuing PPI therapy and magnesium replacement Concomitant use of NEXIUM and St.
In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients PPI use purple power and nexium associated with an increased risk of fundic gland polyps that increases with long-term use, especially beyond one year.
Use shortest duration of PPI therapy appropriate to the condition being treated Concomitant use of NEXIUM and atazanavir or nelfinavir is not recommended due to decreased plasma levels of these anti-retroviral drugs. Consider dose reduction of saquinavir Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time. Esomeprazole may interfere with the absorption of drugs for which gastric pH affects bioavailability eg, ketoconazole, iron salts, and digoxin NEXIUM may increase systemic exposure of cilostazol and one of purple power and nexium active metabolites.